A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

Trial Profile

A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Vobarilizumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms STEADY
  • Sponsors Ablynx
  • Most Recent Events

    • 26 Mar 2018 Results presented in an Ablynx Media Release.
    • 26 Mar 2018 According to an Ablynx media release, primary endpoint (The percentage of subjects who achieved a response at Week 24 according to the composite m BICLA BILAG-based Combined Lupus Assessment score) has not been met.
    • 26 Feb 2018 Status changed to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top